Mitesh

The Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Quetiapine tablets is now available to meet normal demand. As a result the following  Serious Shortage Protocols, will expire at 23.59pm on Friday 13 September 2024. After this date, any prescriptions for Quetiapine tablets must be dispensed in accordance with the prescription, [...]

The post Expiry of nine Quetiapine SSPs (SSP062-SSP070) appeared first on Community Pharmacy England.

MHRA Class 3 Medicines Recall: Evorel Sequi (Theramex HQ UK Ltd) Drug alert number: EL (24)A/41 Date issued: 12 September 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 3 medicines defect information notice for: Evorel Sequi (Theramex HQ UK Ltd) Company name:Theramex HQ UK Ltd Product name: Evorel Sequi, PL 49105/0010 [...]

The post MHRA Class 3 Medicines Recall: Evorel Sequi (Theramex HQ UK Ltd) appeared first on Community Pharmacy England.

Following representations from Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the reimbursement prices for Oestrogel® and Testogel® preparations dispensed in August 2024. On 1 August 2024, there was an increase in the NHS list prices of Oestrogel® and Testogel® preparations manufactured by Besins [...]

The post Oestrogel® and Testogel® – reimbursement price changes for August 2024 appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has retrospectively adjusted the reimbursement prices of Nutrison® water for gastroenteral feeds dispensed from January to July 2024. The list price of Nutrison® water for gastroenteral feeds manufactured by Nutricia Ltd had recently increased but [...]

The post Retrospective reimbursement price adjustments for Nutrison® water for gastroenteral feeds appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued precautionary guidance regarding the of use of valproate in men. This follows results from a retrospective observational study which indicated a possible association between valproate use by men around the time of conception and an increased risk of neurodevelopmental disorders in their children.  Male patients [...]

The post MHRA Drug Safety Update: Valproate use in men appeared first on Community Pharmacy England.